Supplementary Table 1

PMID	Study
32112659	Fujita K, Kato T, Hatano K, et al. Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. *Cancer Sci*. 2020;111(5):1692-1698.
32047956	Kiyohara E, Tanemura A, Nishioka M, et al. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. *Cancer Immunol Immunother*. 2020;69(6):1131-1140.
31570234	Streby KA, Currier MA, Triplet M, et al. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. *Mol Ther*. 2019;27(11):1930-1938.
31409575	Andtbacka RHI, Amatruda T, Nemunaitis J, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. *EBioMedicine*. 2019;47:89-97.
30674657	Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. *Sci Transl Med*. 2019;11(476):eaat9321.
30573564	Reid EG, Looney D, Maldarelli F, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. *Blood Adv*. 2018;2(24):3618-3626.
30234393	García M, Moreno R, Gil-Martin M, et al. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. *Hum Gene Ther*. 2019;30(3):352-364.
29801474	Hirooka Y, Kasuya H, Ishikawa T, et al. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. *BMC Cancer*. 2018;18(1):596. Published 2018 May 25.
29773661	Lauer UM, Schell M, Beil J, et al. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. *Clin Cancer Res*. 2018;24(18):4388-4398.
29748010	Bradbury PA, Morris DG, Nicholas G, et al. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. *Lung Cancer*. 2018;120:142-148.

29653857	Jonker DJ, Tang PA, Kennecke H, et al. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. *Clin Colorectal Cancer*. 2018;17(3):231-239.e7.
29432077	Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. *J Clin Oncol*. 2018;36(14):1419-1427.
29176501	Chesney J, Awasthi S, Curti B, et al. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. *Melanoma Res*. 2018;28(1):44-51.
29027598	Bernstein V, Ellard SL, Dent SF, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. *Breast Cancer Res Treat*. 2018;167(2):485-493.
28981385	Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. *J Clin Oncol*. 2018;36(17):1658-1667.
28923104	Garcia-Carbonero R, Salazar R, Duran I, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. *J Immunother Cancer*. 2017;5(1):71. Published 2017 Sep 19.
28886381	Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy [published correction appears in Cell. 2018 Aug 9;174(4):1031-1032]. *Cell*. 2017;170(6):1109-1119.e10.
23396206	Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med*. 2013;19(3):329-336.
28495911	Streby KA, Geller JI, Currier MA, et al. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. *Clin Cancer Res*. 2017;23(14):3566-3574.
28967558	Geletneky K, Hajda J, Angelova AL, et al. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. *Mol Ther*. 2017;25(12):2620-2634.

28679776	Mell LK, Brumund KT, Daniels GA, et al. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma. *Clin Cancer Res*. 2017;23(19):5696-5702.
27203445	Downs-Canner S, Guo ZS, Ravindranathan R, et al. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. *Mol Ther*. 2016;24(8):1492-1501.
27039845	Noonan AM, Farren MR, Geyer SM, et al. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. *Mol Ther*. 2016;24(6):1150-1158.
9711724	Colombo F, Zanusso M, Casentini L, et al. Gene stereotactic neurosurgery for recurrent malignant gliomas. *Stereotact Funct Neurosurg*. 1997;68(1-4 Pt 1):245-251.
11606381	DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res*. 2001;61(20):7464-7472.
11980996	Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. *J Clin Oncol*. 2002;20(9):2251-2266.
12414631	Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res*. 2002;62(21):6070-6079.
14612551	Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. *Cancer Res*. 2003;63(21):7497-7506.
14693057	Xu RH, Yuan ZY, Guan ZZ, et al. Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer. *Ai Zheng*. 2003;22(12):1307-1310.
15509513	Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. *Mol Ther*. 2004;10(5):958-966.

15647767	Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Gene Ther*. 2005;12(5):437-445.
15803147	Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. *Cancer Gene Ther*. 2005;12(8):673-681.
15961518	Heinzerling L, Künzi V, Oberholzer PA, Kündig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. *Blood*. 2005;106(7):2287-2294.
16257582	Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. *Mol Ther*. 2006;13(1):221-228.
16285179	Voit C, Kron M, Schwürzer-Voit M, Sterry W. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease. *J Dtsch Dermatol Ges*. 2003;1(2):120-125.
16638865	Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. *Clin Cancer Res*. 2006;12(8):2555-2562.
16690359	Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. *Mol Ther*. 2006;14(1):107-117.
16829761	Dempsey MF, Wyper D, Owens J, et al. Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma. *Nucl Med Commun*. 2006;27(8):611-617.
17107303	Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. *Hum Gene Ther*. 2006;17(12):1214-1224.
17121894	Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin Cancer Res*. 2006;12(22):6737-6747.
17228316	Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. *Mol Ther*. 2007;15(3):636-642.

17289893	Hotte SJ, Lorence RM, Hirte HW, et al. An optimized clinical regimen for the oncolytic virus PV701. *Clin Cancer Res*. 2007;13(3):977-985.
17346108	Nakao A, Takeda S, Shimoyama S, et al. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. *Curr Cancer Drug Targets*. 2007;7(2):169-174.
17375076	Freytag SO, Movsas B, Aref I, et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. *Mol Ther*. 2007;15(5):1016-1023.
18253152	Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. *Mol Ther*. 2008;16(3):627-632.
18323793	White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. *Gene Ther*. 2008;15(12):911-920.
18495536	Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial [published correction appears in Lancet Oncol. 2008 Jul;9(7):613]. *Lancet Oncol*. 2008;9(6):533-542.
18615711	Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. *Head Neck*. 2008;30(8):1045-1051.
19018254	Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. *Mol Ther*. 2009;17(2):389-394.
19092859	Li JL, Liu HL, Zhang XR, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. *Gene Ther*. 2009;16(3):376-382.
19242097	Chang J, Zhao X, Wu X, et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. *Cancer Biol Ther*. 2009;8(8):676-682.
19915919	Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. *Ann Surg Oncol*. 2010;17(3):718-730.
19884534	Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding,

	second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. *J Clin Oncol*. 2009;27(34):5763-5771.
19935775	Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. *Mol Ther*. 2010;18(2):429-434.
20103634	Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. *Cancer Res*. 2010;70(3):875-882.
20484020	Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. *Clin Cancer Res*. 2010;16(11):3067-3077.
20486770	Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. *Hum Gene Ther*. 2010;21(9):1119-1128.
20501623	Nokisalmi P, Pesonen S, Escutenaire S, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. *Clin Cancer Res*. 2010;16(11):3035-3043.
20664527	Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. *Mol Ther*. 2010;18(10):1874-1884.
20670951	Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. *Clin Cancer Res*. 2010;16(15):4005-4015.
20926400	Comins C, Spicer J, Protheroe A, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. *Clin Cancer Res*. 2010;16(22):5564-5572.
20978148	Kimball KJ, Preuss MA, Barnes MN, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. *Clin Cancer Res*. 2010;16(21):5277-5287.
21102422	Nakao A, Kasuya H, Sahin TT, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. *Cancer Gene Ther*. 2011;18(3):167-175.

21304001	Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. *Clin Cancer Res*. 2011;17(4):888-895.
21630267	Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. *Int J Cancer*. 2012;130(8):1937-1947.
21673660	Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. *Mol Ther*. 2011;19(9):1737-1746.
21772252	Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. *Mol Ther*. 2011;19(10):1913-1922.
21886163	Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature*. 2011;477(7362):99-102. Published 2011 Aug 31.
22316603	Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. *Clin Cancer Res*. 2012;18(7):2080-2089.
22700953	Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. *Sci Transl Med*. 2012;4(138):138ra77.
22871663	Galanis E, Markovic SN, Suman VJ, et al. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. *Mol Ther*. 2012;20(10):1998-2003.
22886613	Morris DG, Feng X, DiFrancesco LM, et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. *Invest New Drugs*. 2013;31(3):696-706.
23088985	Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. *J Urol*. 2012;188(6):2391-2397.
23493351	Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. *Clin Cancer Res*. 2013;19(10):2734-2744.

23756180	Kim KH, Dmitriev IP, Saddekni S, et al. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. *Gynecol Oncol*. 2013;130(3):518-524.
24484178	Kaufman HL, Kim DW, Kim-Schulze S, et al. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. *Hum Gene Ther*. 2014;25(5):452-460.
24553100	Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. *Mol Ther*. 2014;22(5):1056-1062.
24572293	Markert JM, Razdan SN, Kuo HC, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. *Mol Ther*. 2014;22(5):1048-1055.
25292189	Zeh HJ, Downs-Canner S, McCart JA, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. *Mol Ther*. 2015;23(1):202-214.
25294913	Sborov DW, Nuovo GJ, Stiff A, et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. *Clin Cancer Res*. 2014;20(23):5946-5955.
25307519	Burke MJ, Ahern C, Weigel BJ, et al. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. *Pediatr Blood Cancer*. 2015;62(5):743-750.
25424857	Roulstone V, Khan K, Pandha HS, et al. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. *Clin Cancer Res*. 2015;21(6):1305-1312.
25469725	El-Sherbiny YM, Holmes TD, Wetherill LF, et al. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. *Clin Exp Immunol*. 2015;180(1):98-107.
25531693	Cripe TP, Ngo MC, Geller JI, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. *Mol Ther*. 2015;23(3):602-608.
25714011	Hemminki O, Parviainen S, Juhila J, et al. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. *Oncotarget*. 2015;6(6):4467-4481.
25728527	Kolb EA, Sampson V, Stabley D, et al. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. *Pediatr Blood Cancer*. 2015;62(5):751-758.

26014293	Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *J Clin Oncol*. 2015;33(25):2780-2788.
26073886	Park SH, Breitbach CJ, Lee J, et al. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. *Mol Ther*. 2015;23(9):1532-1540.
26862025	van Putten EH, Wembacher-Schröder E, Smits M, Dirven CM. Magnetic Resonance Imaging-Based Assessment of Gadolinium-Conjugated Diethylenetriamine Penta-Acetic Acid Test-Infusion in Detecting Dysfunction of Convection-Enhanced Delivery Catheters. *World Neurosurg*. 2016;89:272-279.
27298410	Puzanov I, Milhem MM, Minor D, et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. *J Clin Oncol*. 2016;34(22):2619-2626.
27322463	Kelly KJ, Wong J, Gönen M, et al. Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. *EBioMedicine*. 2016;7:94-99.
27464544	Gao YD, Chen GL, Guo PD, Yang XL. *Zhonghua Yi Xue Za Zhi*. 2016;96(27):2173-2175.
28177438	Husseini F, Delord JP, Fournel-Federico C, et al. Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. *Ann Oncol*. 2017;28(1):169-174.
28289863	Mahalingam D, Fountzilas C, Moseley J, et al. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. *Cancer Chemother Pharmacol*. 2017;79(4):697-703.
28439108	Dispenzieri A, Tong C, LaPlant B, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. *Leukemia*. 2017;31(12):2791-2798.
28755959	Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. *Urol Oncol*. 2018;36(10):440-447.
28756871	Cohn DE, Sill MW, Walker JL, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG

	Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2017;146(3):477-483.
30691536	Machiels JP, Salazar R, Rottey S, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). *J Immunother Cancer*. 2019;7(1):20. Published 2019 Jan 28.